{"id":622487,"date":"2026-08-05T21:23:16","date_gmt":"2026-08-05T21:23:16","guid":{"rendered":"https:\/\/www.europesays.com\/ie\/622487\/"},"modified":"2026-08-05T21:23:16","modified_gmt":"2026-08-05T21:23:16","slug":"johnson-johnson-jnj-could-be-10-overvalued-following-leadership-change","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ie\/622487\/","title":{"rendered":"Johnson & Johnson (JNJ) Could Be 10% Overvalued Following Leadership Change"},"content":{"rendered":"\n

Get insights on thousands of stocks<\/a> from the global community of over 7 million individual investors at Simply Wall St. <\/p>\n

Johnson & Johnson (JNJ) is back in focus after longtime executive Jennifer Taubert retired as Executive Vice President, Worldwide Chairman, Innovative Medicine, with experienced biopharmaceutical leader Tom Cavanaugh set to succeed her. <\/p>\n

See our latest analysis for Johnson & Johnson.<\/a> <\/p>\n

Johnson & Johnson’s share price has had a strong run in 2026, with a year to date share price return of 22.95% and a 90 day share price return of 13.49%, while the 1 year total shareholder return of 53.04% reflects both capital gains and reinvested income. <\/p>\n

If you are looking beyond Johnson & Johnson and want to see where healthcare and AI intersect, this is a good moment to check out 41 healthcare AI stocks<\/a> <\/p>\n

After a 53.04% total return over the past year and fresh optimism around Johnson & Johnson’s pipeline and robotics push, the real test now is simple: Does the current valuation still offer a compelling risk reward for new buyers? <\/p>\n

Most Popular Narrative: 10.4% Overvalued <\/p>\n

Compared with Johnson & Johnson’s last close at $254.93, the most followed narrative from user Ben_Dur points to a fair value of $230.82 using a 6.978% discount rate and suggests the stock is moderately ahead of that estimate. <\/p>\n

\n

Successful AI-accelerated drug launches (oncology\/immunology) with multi-hundred\u2011million to multi\u2011billion revenue impact. <\/p>\n<\/blockquote>\n

Read the complete narrative.<\/a> <\/p>\n

Want to see how this AI driven pipeline vision justifies a higher price tag for Johnson & Johnson? The revenue trajectory, margin profile and assumed market multiple are all wired into this valuation story. <\/p>\n

Result: Fair Value of $230.82 (OVERVALUED)<\/strong> <\/p>\n

Have a read of the narrative in full and understand what’s behind the forecasts.<\/a> <\/p>\n

However, this Johnson & Johnson AI story can shift quickly if regulators push back on AI generated evidence, or if rivals move faster with superior AI platforms. <\/p>\n

Find out about the key risks to this Johnson & Johnson narrative.<\/a> <\/p>\n

Another View On Johnson & Johnson’s Valuation <\/p>\n

The user narrative points to Johnson & Johnson trading about 10.4% above a $230.82 fair value. Our DCF model takes a very different angle. It suggests the stock at $254.93 is trading below an estimated future cash flow value of $352.97, which presents JNJ as undervalued. Which perspective do you find more compelling right now? <\/p>\n

Look into how the SWS DCF model arrives at its fair value.<\/a> <\/p>\n

\"JNJ<\/a> JNJ Discounted Cash Flow as at Aug 2026 <\/p>\n

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Johnson & Johnson for example<\/a>). We show the entire calculation in full. You can track the result in your watchlist<\/a> or portfolio<\/a> and be alerted when this changes, or use our stock screener to discover 52 high quality undervalued stocks<\/a>. If you save a screener<\/a> we even alert you when new companies match – so you never miss a potential opportunity. <\/p>\n

Next Steps <\/p>\n

With sentiment around Johnson & Johnson running high, this is a good time to move quickly and test the thesis against the data yourself. To see what investors are currently optimistic about, take a closer look at the 2 key rewards<\/a>. <\/p>\n

Looking for more investment ideas beyond Johnson & Johnson? <\/p>\n

Do not stop with Johnson & Johnson when there are other potentially interesting stocks to review. Use the screeners below to quickly spot ideas that match your style. <\/p>\n

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.<\/strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. <\/p>\n

Companies discussed in this article include JNJ<\/a>. <\/p>\n

Have feedback on this article? Concerned about the content? <\/strong>Get in touch<\/strong><\/a> with us directly.<\/strong> Alternatively, email editorial-team@simplywallst.com<\/a> <\/p>\n","protected":false},"excerpt":{"rendered":"Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply…\n","protected":false},"author":2,"featured_media":622488,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[275],"tags":[18,25947,135,475,474,19,17,2994],"class_list":["post-622487","post","type-post","status-publish","format-standard","has-post-thumbnail","category-healthcare","tag-eire","tag-fair-value","tag-health","tag-health-care","tag-healthcare","tag-ie","tag-ireland","tag-johnson-johnson"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ie\/117045009313234001","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/posts\/622487","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/comments?post=622487"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/posts\/622487\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/media\/622488"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/media?parent=622487"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/categories?post=622487"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/tags?post=622487"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}